Results 81 to 90 of about 6,610 (196)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) [PDF]

, 2015
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity.
Di Fabio, Sandra, Paolillo, Piermichele, Andrea Dotta, Sandra Di Fabio, Chirico, Gaetano, Bollani, Lina, Paolo Manzoni, Dotta, Andrea, Lanari, Marcello, Piermichele Paolillo, Boldrini, Antonio, Orfeo, Luigi, Antonio Boldrini, Del Vecchio, Antonello, Romagnoli, Costantino, Manzoni, Paolo, Lina Bollani, Costantino Romagnoli, Antonello Del Vecchio, Eugenio Baraldi, Gaetano Chirico, Stronati, Mauro, null null, BARALDI, EUGENIO, Luigi Orfeo, Marcello Lanari, Mauro Stronati   +26 more
core   +1 more source

Development and validation of an enzyme linked immunosorbent assay for palivizumab serum determination.

, 2013
Palivizumab (Synagis) is a humanized monoclonal antibody (IgG1K) composed of 95 percent human and 5 percent murine sequences. It is directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
Ragazzi M., BLOISE, NORA, Montagna M, Avanzini MA, Di Comite A, Iommiello V, VISAI, LIVIA, Stronati M   +7 more
core  

Respiratory syncytial virus immunization patterns in Germany, 2015–2020

Human Vaccines & Immunotherapeutics
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated
Moritz Wick, Roman Kliemt, Anahita Poshtiban, Nils Kossack, Gerhard-Paul Diller, Samira Soudani, Mathieu Bangert, Rolf Kramer, Oliver Damm   +8 more
doaj   +1 more source

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA

Zdravniški Vestnik, 2002
Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children under 12 months of age. Premature children and those with chronic lung disease are at increased risk for severe RSV infection.
Marko Pokorn, Milan Čižman, Janez Primožič, Janez Babnik, Silvo Kopriva, Zdravko Roškar   +5 more
doaj  

Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group

Pediatric Health, Medicine and Therapeutics, 2014
Gerard Notario,1 Pamela Vo,2 Katherine Gooch,2 Roger Deaton,3 Xionghua Wu,4 Brian Harris,4 Parthiv J Mahadevia,4 Pablo J Sánchez51Clinical Development and Medical Affairs, 2Global Heath Economics and Outcomes Research, 3Statistics, AbbVie Inc ...
Notario G, Vo P, Gooch K, Deaton R, Wu X, Harris B, Mahadevia PJ, Sánchez PJ   +7 more
doaj  

Kaplan-Meier survival curves of RSV hospitalization rate stratified by palivizumab treatment.

, 2014
There was statistically significant difference between palivizumab and control group (p = 0.001, log-rank test).
Fu-Yuan Huang (230861), Chyong-Hsin Hsu (589793), Nan-Chang Chiu (230863), Li-Chuan Weng (416264), Han-Yang Hung (589795), Li-Min Huang (185153), Hsin-An Kao (589796), Hsin Chi (230868), Jui-Hsing Chang (589794), Yu-Ying Chiu (416267), Luan-Yin Chang (185145)   +10 more
core   +1 more source

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection

, 2017
Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in children below the age of 5 y. It is associated with up to 63% of all acute respiratory infections and up to 81% of all viral lower respiratory tract infections ...
Bernhard Resch
core   +1 more source

Valoración económica del palivizumab en prematuros en la Seguridad Social en Costa Rica [PDF]

, 2020
RESUMEN Introducción: El virus sincitial respiratorio afecta la salud de prematuros y el palivizumab puede reducir sus complicaciones. En Costa Rica se desconoce la eficiencia del uso de esta tecnología sanitaria.
Collazo Herrera, Manuel, Jiménez Herrera, Luis Guillermo, Gálvez González, Ana María   +2 more
core  

DISTRIBUTION PROFILE OF PALIVIZUMAB IN BRAZIL: ANALYSIS OF REGIONAL DISTRIBUTION BETWEEN 2014 AND 2024 FOR PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN CHILDREN CARED FOR BY THE UNIFIED HEALTH SYSTEM (SUS)

Brazilian Journal of Infectious Diseases
Introduction/Objectives: Palivizumab is recommended to prevent severe RSV infections in children at higher risk, such as preterm infants (gestational age ≤28 weeks) and children under 2 years of age with chronic lung disease or congenital heart disease ...
Jônatas Cunha Barbosa Lima, Daniel Moreira Alves da Silva, Luciana de Vasconcelos Rebouças, Kllysmann Santos Ribeiro, Thamela Cristiny Simão Alves, Vanessa Cristina Ribeiro, Matheus Malveira Vaz, Rodrigo Ramos Sena, Nara Amanda Laismann, Ana Liani Beisl Oliveira, Rafaela Tavares Peixoto, Luiz Henrique Costa, Marco Aurelio Pereira   +12 more
doaj   +1 more source

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

Objective: To assess the cost effectiveness of palivizumab (a preventative treatment against severe respiratory syncytial virus [RSV] infection) in children at high risk of hospitalisation, i.e. preterm infantsBronchopulmonary-dysplasia, Congenital-heart-
Maximilian Lebmeier, Wolfgang Wittenberg, Mark J.C. Nuijten   +2 more
core